AstraZeneca completes acquisition of Pearl Therapeutics
Posted: 28 June 2013 | | No comments yet
AstraZeneca announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics…
![AstraZeneca](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/astrazeneca-2-300x278.jpg)
![AstraZeneca](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/astrazeneca-2-300x278.jpg)
AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl’s shares.
As previously announced, the acquisition gives AstraZeneca access to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides a platform for future combination products